<DOC>
	<DOCNO>NCT01038063</DOCNO>
	<brief_summary>A community-based , open-label , cluster-randomised longitudinal study child randomize accord village health worker catchment area compare safety effectiveness repeat treatment artemether-lumefantrine ( AL ) 3-year period child 4-48 month repeat treatment dihydroartemisinin-piperaquine ( DHA-PPQ ) .</brief_summary>
	<brief_title>Safety Effectiveness Artemisinin-based Combination Therapies ( ACTs ) With Repeated Treatments Uncomplicated Falciparum Malaria Over Three-year Period</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Inclusion criterion 1 . Aged 4 month 11 month time randomization 2 . Bodyweight â‰¥ 5 kg time randomization 3 . Provision inform consent parent guardian 4 . Intention stay study area time study Exclusion criterion 1 . Ongoing participation another clinical study involve ongoing schedule treatment medicinal product 2 . Intent reside outside catchment area course study 3 . Known hypersensitivity study drug randomize 4 . Known preexist hearing problem neurological impairment 5 . Known need time randomization concomitant prohibit medication 6 . Suspected noncompliance followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>